Let me start with a question. How many people in the world do you think still need treatment or protection from a neglected tropical disease?
A few million? Maybe tens of millions, scattered across remote villages most of us will never visit?
The answer is 1.41 billion. That is roughly one in every six people on earth.
So let us retire the first piece of common sense right away. These diseases are not neglected because they are rare. They are not rare. They are among the most common conditions on the planet. They are neglected because of who they affect: people living in poverty, in rural and remote places, in conflict zones, in communities whose voices rarely reach a budget committee.
“Neglected” is not a medical term but a point blank confession.
This month, Africa’s biggest public health conference opens in Addis Ababa. I went through the full programme: 165 sessions over five days covering financing, sovereignty, manufacturing, AI, climate and pandemics.
Only one session has neglected tropical diseases in its title. One.
The continent carries 45% of the world’s NTD burden, measured in years of healthy life lost.
Earlier this month I joined a continental workshop on the Lusaka Agenda, where governments and partners spent three days on how Africa can finance and own its health. Manufacturing, pooled procurement and regulation were all on the table. The step that comes before them, research and development, deserves a firmer place in that conversation, because it decides which medicines exist in the first place.
Nobody in those rooms is against NTDs. That is the point. Neglect does not need opponents. It only needs everyone to be busy with something else.
Here is where common sense can get dangerous, because there is 'good news.'
WHO’s mid-term review of the 2021–2030 NTD road map, published this year, shows real progress. By June 2026, 63 countries had eliminated at least one NTD, up from 42 at the end of 2020. Togo became the first country to eliminate four. The number of people needing interventions has fallen by more than a third since 2010. More than 11.5 billion medicine doses have been delivered to over 110 countries. New treatments have reached patients, including fexinidazole, the first all-oral treatment for sleeping sickness.
Common sense is to hear this and relax because, we are winning. These diseases are on their way out.
Read the next line in the same report. The pace of progress is insufficient to reach most of the 2030 targets. The disease burden, which fell steadily for years, has stagnated since 2020. The two diseases targeted for complete eradication, Guinea-worm and yaws, both need to speed up. Dedicated funding for yaws has almost disappeared since 2022.
The success stories are real. But we have started using them as a sedative.
Now the money, because this is where neglect stops being a word and becomes a decision with a name and a date on it.
Between 2018 and 2024, three funders (the United States, the United Kingdom and the Gates Foundation) provided 79% of all NTD funding. Think about that. The health of over a billion people rested on the budget decisions of three institutions.
Then those decisions changed. The United Kingdom cut its NTD funding by 91% in a single year, from US$89 million in 2021 to around US$12 million by 2024. In 2025 the United States terminated several major NTD programmes. WHO reported that by June 2025, 47 mass treatment campaigns affecting 143 million people had been delayed. Without alternative delivery, more than 55 million tablets could expire in Africa by the end of that year.
Read that again slowly. The medicines existed. They were donated. They were sitting in warehouses. What disappeared was the money for the truck, the fuel, the community drug distributor’s allowance, the person who records who took the tablet.
Common sense is to think that the hard part of global health is inventing the medicine, right? Very often, the hard part is the last 50 kilometres.
Here is the part that should make us uncomfortable. In most endemic countries, NTD services are still not included in the universal health coverage packages governments are building. We talk about health for all, and then we draw the line of “all” just short of these diseases.
And when people pay for care themselves, the cost bites hardest exactly where these diseases live. WHO estimates that around 24% of the people who need NTD interventions were pushed into, or deeper into, poverty by health spending. These are diseases of poverty that then create more poverty. It is a loop, and our systems are built in a way that keeps it turning.
Yet the same report describes Mauritania, which estimates it would need less than 1% of its domestic health spending to meet its 2030 NTD targets.
Less than one percent. So the question was never really whether we can afford it. It is whether we are paying attention.
Let me offer three ideas that run against the grain:
1. Elimination is not the finish line. It is the most dangerous moment. When a disease nearly disappears, the money leaves, the specialists retire or move on, and the diagnostics can no longer confirm whether transmission has truly stopped. WHO’s report warns of exactly this, and of documented drug resistance on top. We celebrate the final mile with first-mile tools, then act surprised when diseases return. The moment we declare victory is the moment we need to protect it most.
2. Health sovereignty will be judged by the diseases nobody else will pay for. Africa is rightly talking about owning its health future, from manufacturing and financing to research. But sovereignty is easy to claim for the diseases the world already funds. The real test is the diseases with no global fund, no pooled mechanism and no lobby. NTDs have no equivalent of the Global Fund or Gavi. If sovereignty means anything, it means putting these diseases in national budgets and national research agendas because no one else will.
3. The research question is a sovereignty question. We cannot manufacture what no one has invented. Diagnostics for some diseases still cannot confirm that transmission has stopped, and medicines are missing or failing for others. Yet we know this can change. Since 2003, DNDi, has developed 17 treatments for six deadly diseases with partners, many of them tested in African hospitals by African scientists. The science was never the barrier, attention was. Every time a government funds research, it can ask who the results are for and how they will reach the people who need them. That is not charity but a smart condition on public money, taxpayers money!
Somewhere tonight, a woman with swollen legs from lymphatic filariasis is wondering why the medicine distributor did not come this year. She has never heard of the “global health architecture.” She will not read the mid-term evaluation. She does not know that her village was one of 143 million people whose campaign was delayed.
But she lives inside every decision we make in conference halls, in budget meetings and in the agendas we write.
Common sense says these diseases are neglected because they are hard to fix.
Uncommon sense says they are hard to fix because we neglect them.
The difference between those two sentences is a choice. And it is still ours to make!